Publication: Systemic treatment of renal cell cancer: A comprehensive review.
No Thumbnail Available
Identifiers
Date
2017-09-01
Authors
Sánchez-Gastaldo, Amparo
Kempf, Emmanuelle
González Del Alba, Aránzazu
Duran, Ignacio
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
Description
MeSH Terms
Antineoplastic Agents
Carcinoma, Renal Cell
Humans
Immunotherapy
Kidney Neoplasms
Molecular Targeted Therapy
Carcinoma, Renal Cell
Humans
Immunotherapy
Kidney Neoplasms
Molecular Targeted Therapy
DeCS Terms
CIE Terms
Keywords
Angiogenesis, Immunotherapy, Monoclonal antibody, Renal cell cancer, Targeted therapy, Tyrosine-kinase inhibitor, mTOR inhibitor